ArticleNature communications2026
Bioinspired microcapsule reactor with engineered probiotics for IBD therapy.
Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Although probiotic-based bionic strategies show therapeutic promise for inflammatory bowel disease, their clinical translation is limited by poor gastric acid survival, inefficient intestinal colonization and inadequate targeting. Inspired by the multi-level cooperative mechanism of defense protection-danger sensing-tissue repair observed in coral communities, we developed a core-shell bionic microcapsule reactor (MY-E@SS). Here we show that the multifunctional bionic shell enables safe delivery of engineered bacteria through the gastrointestinal tract. Upon reaching inflamed intestinal sites, these bacteria sense the pathological microenvironment and responsively release an anti-inflammatory peptide. In a male murine model of inflammatory bowel disease, this system exhibited excellent biocompatibility and pronounced therapeutic efficacy, restoring intestinal barrier integrity, attenuating systemic inflammation and oxidative stress, modulating respiratory metabolism, and reestablishing microbial homeostasis. Mechanistically, therapeutic effects were attributed to inhibition of TNF-α/NF-κB signaling pathway. This work provides an intelligent platform to modulate inflammatory microenvironments and advance therapies for complex diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.